Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mira Patel

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
British Journal of Clinical Pharmacology|February 12, 2019
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell diseaseAthiwat Hutchaleelaha, Mira Patel, Carla Washington, et al.
Cancers|February 25, 2023
A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of LifeMira Patel, William Tyler Turchan, Christopher G Morris, et al.
Veterinary Surgery : VS|November 3, 2017
Arterial anomalies of the celiac trunk and median arcuate ligament compression in dogs and cats assessed by computed tomography angiographyHélène M Le Pommellet, Brian A Scansen, Dimitria A Mathys, et al.
Journal of the American Pharmacists Association : Japha|March 13, 2017
Patient perceptions of a pharmacy star rating modelTerri L Warholak, Mira Patel, Meagen Rosenthal, et al.
Nanoscale Advances|July 24, 2025
Insights into the physicochemical interactions of ionic liquid-coated polymeric nanoparticles with red blood cellsChristine M Hamadani, George R Taylor, Amber Cecil, et al.
ACS Medicinal Chemistry Letters|August 20, 2025
Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization InhibitorZhe Li, Carsten Alt, Kobina Dufu, et al.
Blood|January 19, 2019
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell diseaseJo Howard, Claire Jane Hemmaway, Paul Telfer, et al.
Clinical Pharmacology and Therapeutics|September 2, 2025
Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and PatientsEleanor A Lisbon, R Clark Brown, Andrew Redfern, et al.
JTO Clinical and Research Reports|January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 TrialNiels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
British Journal of Haematology|March 24, 2023
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine modelKobina Dufu, Carsten Alt, Steven Strutt, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
British Journal of Clinical Pharmacology|February 12, 2019
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell diseaseAthiwat Hutchaleelaha, Mira Patel, Carla Washington, et al.
Cancers|February 25, 2023
A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of LifeMira Patel, William Tyler Turchan, Christopher G Morris, et al.
Veterinary Surgery : VS|November 3, 2017
Arterial anomalies of the celiac trunk and median arcuate ligament compression in dogs and cats assessed by computed tomography angiographyHélène M Le Pommellet, Brian A Scansen, Dimitria A Mathys, et al.
Journal of the American Pharmacists Association : Japha|March 13, 2017
Patient perceptions of a pharmacy star rating modelTerri L Warholak, Mira Patel, Meagen Rosenthal, et al.
Nanoscale Advances|July 24, 2025
Insights into the physicochemical interactions of ionic liquid-coated polymeric nanoparticles with red blood cellsChristine M Hamadani, George R Taylor, Amber Cecil, et al.
ACS Medicinal Chemistry Letters|August 20, 2025
Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization InhibitorZhe Li, Carsten Alt, Kobina Dufu, et al.
Blood|January 19, 2019
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell diseaseJo Howard, Claire Jane Hemmaway, Paul Telfer, et al.
Clinical Pharmacology and Therapeutics|September 2, 2025
Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and PatientsEleanor A Lisbon, R Clark Brown, Andrew Redfern, et al.
JTO Clinical and Research Reports|January 26, 2026
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 TrialNiels Reinmuth, Sébastien Couraud, Luis Paz-Ares, et al.
British Journal of Haematology|March 24, 2023
GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine modelKobina Dufu, Carsten Alt, Steven Strutt, et al.
Pageof 4